Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition

Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cyclic Peptide Library Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

This market research report examines the global cyclic peptide library market, projected to grow from USD 3.75 billion in 2026 to USD 9.86 billion by 2032 at a CAGR of 16.32%. It evaluates discovery technologies, artificial intelligence applications, regional capabilities, collaborative ecosystems, and strategic priorities shaping market development.

Market Overview

Cyclic peptide libraries support the discovery and optimization of constrained peptides for therapeutic research, target validation, and molecular screening. Their value stems from chemical diversity, conformational restriction, and the ability to investigate interactions that may be difficult to address with conventional small molecules or linear peptides.

The market combines capabilities across peptide synthesis, assay development, analytical characterization, computational design, and translational biology. These insights support strategic planning by highlighting the technologies and capabilities most likely to influence platform performance and commercial opportunity.

Evolution of Cyclic Peptide Discovery

Discovery workflows increasingly integrate library design, automated synthesis, high-throughput screening, and iterative sequence optimization. Researchers are placing greater emphasis on permeability, metabolic stability, target selectivity, manufacturability, and reproducibility.

Standardized data capture and improved analytical methods enable more consistent candidate comparisons across platforms. Understanding these developments can guide technology investments, partnership decisions, and market entry strategies.

Artificial Intelligence in Library Design and Screening

Artificial intelligence and machine learning are being applied to:

. Prioritize promising peptide sequences

. Identify structure-activity relationships

. Predict physicochemical and developability properties

. Guide successive cycles of library generation

. Reduce experimental search spaces

Model performance depends on representative training data, transparent validation, experimental confirmation, and effective management of bias and uncertainty. Organizations combining AI with disciplined laboratory feedback loops may gain a competitive advantage while reducing technical and development risks.

Regional Market Dynamics

. North America benefits from advanced biomedical research, specialized screening infrastructure, and strong academic-industry translation.

. Europe combines chemical biology expertise with coordinated research and regulatory networks.

. Asia-Pacific is supported by expanding biotechnology capacity, automation investment, and established pharmaceutical research ecosystems.

. Latin America is developing capabilities through research institutions and collaborative networks.

. The Middle East is strengthening life-science innovation infrastructure and technology-enabled healthcare programs.

. Africa presents emerging opportunities related to scientific capacity building, local health priorities, and international partnerships.

Collaborative and Country-Level Capabilities

ASEAN economies are investing in biotechnology infrastructure, talent, and cross-border research. BRICS members offer varied scientific, manufacturing, and healthcare capabilities, while the European Union benefits from coordinated programs and shared regulatory considerations. G7 countries contribute advanced screening, medicinal chemistry, data science, and translational expertise. GCC states are expanding research diversification, and NATO members benefit from established scientific cooperation.

The United States, Canada, the United Kingdom, Germany, France, Italy, and Spain maintain established peptide research and pharmaceutical ecosystems. Japan and South Korea are strong in automation and precision manufacturing, while China is expanding synthesis, screening, and biopharmaceutical development. India offers growing chemistry, contract research, and scalable laboratory capabilities. Australia, Brazil, and Mexico continue to strengthen specialized and regional research networks. Russia retains chemistry and biology expertise, although access, regulatory conditions, and collaboration risks require careful evaluation.

Strategic Priorities

Industry leaders should:

. Design libraries around defined biological questions and downstream development criteria

. Prioritize reproducible synthesis, orthogonal assay validation, and analytical characterization

. Develop interoperable data systems and responsible AI governance

. Use regional partnerships to access specialized capabilities

. Address intellectual property, regulation, supply resilience, and workforce requirements early

Key Takeaways from This Report

. The market is forecast to reach USD 9.86 billion by 2032, expanding at a CAGR of 16.32%.

. Integrated, data-rich discovery workflows are replacing isolated synthesis and screening activities.

. AI is improving sequence prioritization and optimization but requires rigorous experimental validation.

. Regional specialization creates partnership, investment, and market expansion opportunities.

. Reproducibility, developability, data integration, and supply resilience are central to competitive platform development.

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cyclic Peptide Library Market, by Type

7.1. Introduction

7.2. Synthetic Cyclic Peptides

7.3. Natural Cyclic Peptides

8. Cyclic Peptide Library Market, by Product Format

8.1. Introduction

8.2. Lipopeptides

8.3. Cyclotides

8.4. Cyclic Dipeptides

9. Cyclic Peptide Library Market, by Method

9.1. Introduction

9.2. Solid-Phase Peptide Synthesis

9.3. Recombinant Biosynthesis

9.4. Liquid-Phase Peptide Synthesis

9.5. Hybrid Technology

10. Cyclic Peptide Library Market, by Route Of Administration

10.1. Introduction

10.2. Topical

10.3. Oral

10.4. Injectable

11. Cyclic Peptide Library Market, by Application

11.1. Introduction

11.2. Therapeutics

11.3. Research & Development

11.4. Environmental Protection

11.5. Diagnostics & Biosensors

12. Cyclic Peptide Library Market, by End-User

12.1. Introduction

12.2. Pharmaceutical Companies

12.3. Contract Research & Manufacturing Organizations

12.4. Biotechnology Companies

12.5. Academic Research Institutes

13. Cyclic Peptide Library Market, by Region

13.1. Introduction

13.2. Asia-Pacific

13.3. North America

13.4. Latin America

13.5. Europe

13.6. Middle East

13.7. Africa

14. Cyclic Peptide Library Market, by Group

14.1. Introduction

14.2. ASEAN

14.3. GCC

14.4. European Union

14.5. BRICS

14.6. G7

14.7. NATO

15. Cyclic Peptide Library Market, by Country

15.1. Introduction

15.2. United States

15.3. Canada

15.4. Mexico

15.5. Brazil

15.6. United Kingdom

15.7. Germany

15.8. France

15.9. Russia

15.10. Italy

15.11. Spain

15.12. China

15.13. India

15.14. Japan

15.15. Australia

15.16. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025

16.2. Market Concentration Analysis, 2025

16.2.1. Concentration Ratio (CR)

16.2.2. Herfindahl Hirschman Index (HHI)

16.3. Recent Developments & Impact Analysis, 2025

16.4. Product Portfolio Analysis, 2025

16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Amgen Inc.

17.2. Astellas Pharma Inc.

17.3. AstraZeneca PLC

17.4. Bicycle Therapeutics Ltd

17.5. Boehringer Ingelheim International GmbH

17.6. Evotec SE

17.7. Merck & Co., Inc.

17.8. Novartis AG

17.9. PeptiDream Inc.

17.10. Pfizer Inc.

17.11. Roche Holding AG

18. Key Experts

For more information about this report visit https://www.researchandmarkets.com/r/rqo7xx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.